Literature DB >> 19242262

Evidence of a decrease in CD4 recovery once back on antiretroviral therapy after sequential > or =6 weeks antiretroviral therapy interruptions.

Emmanouil Papasavvas, Andrea Foulkes, Xiaohong Li, Jay R Kostman, Karam C Mounzer, Luis J Montaner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19242262      PMCID： PMC2726754          DOI： 10.1097/QAI.0b013e3181966b0c

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  7 in total

1.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

3.  Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.

Authors:  Mark Dybul; Elizabeth Nies-Kraske; Marybeth Daucher; Kurt Hertogs; Claire W Hallahan; Gyorgy Csako; Christian Yoder; Linda Ehler; Peter A Sklar; Michael Belson; Bertha Hidalgo; Julia A Metcalf; Richard T Davey; Diane M Rock Kress; April Powers; Anthony S Fauci
Journal:  J Infect Dis       Date:  2003-07-10       Impact factor: 5.226

4.  Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals.

Authors:  Javier Martinez-Picado; Simon D W Frost; Nuria Izquierdo; K Morales-Lopetegi; Silvia Marfil; Teresa Puig; Cecilia Cabrera; Bonaventura Clotet; Lidia Ruiz
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

Authors:  M Dybul; T W Chun; C Yoder; B Hidalgo; M Belson; K Hertogs; B Larder; R L Dewar; C H Fox; C W Hallahan; J S Justement; S A Migueles; J A Metcalf; R T Davey; M Daucher; P Pandya; M Baseler; D J Ward; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

Review 6.  Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparing.

Authors:  Livio Azzoni; Emmanouil Papasavvas; Luis J Montaner
Journal:  Curr HIV Res       Date:  2003-07       Impact factor: 1.581

7.  Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

Authors:  Emmanouil Papasavvas; Jay R Kostman; Karam Mounzer; Robert M Grant; Robert Gross; Cele Gallo; Livio Azzoni; Andrea Foulkes; Brian Thiel; Maxwell Pistilli; Agnieszka Mackiewicz; Jane Shull; Luis J Montaner
Journal:  PLoS Med       Date:  2004-12-28       Impact factor: 11.069
  7 in total
  1 in total

1.  Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Authors:  Emmanouil Papasavvas; Andrea Foulkes; Xiangfan Yin; Jocelin Joseph; Brian Ross; Livio Azzoni; Jay R Kostman; Karam Mounzer; Jane Shull; Luis J Montaner
Journal:  Immunology       Date:  2015-05-19       Impact factor: 7.397
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.